Parabilis Medicines, Inc.
PBLS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001657677
No open-market purchases or sales by Parabilis Medicines, Inc. insiders were filed in the last 90 days; 79 institutions reported holding it in 13F filings for Q2 2026, worth $2.71B in total; no superinvestor holds it.
Key figures
- Market capNo recent share count in SEC filings
- –
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +79 vs. previous quarter
- 79
- 13F valueReported value at the end of Q2 2026
- $2.71B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, Q2 FY2026
- $148.0K
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 15, 2026.
- Short interest
- 9.25M
- Shares sold short
- Change
- +988.6K
- +12.0% vs. previous
- Days to cover
- 9.50
- At average daily volume
Superinvestors holding PBLS, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding PBLS at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Parabilis Medicines, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 22, 2026 (view filing)4:55 PM ET | Jul 20-22 | 2 days | RA Capital Healthcare Fund LP and 4 othersDirector, 10% Owner | PPurchaseVoting Common Stock | +244.6K | $28.29 | +$6.92M | +0.9%26.5M after | 6 lots |
| Jun 29, 2026 (view filing)10:41 AM ET | Jun 11 | 18 daysLate | Soleus Capital, LLC and 8 others10% Owner | PPurchaseCommon Stock, par value $0.0001 per share | +500.0K | $20.00 | +$10.0M | +328.9%652.0K after | 2 lots |
| Jun 16, 2026 (view filing) | Jun 12-15 | 4 days | Sebulsky AlanDirector | PPurchase | +17.5K | $27.06 | +$473.6K | +140.0%30.0K after | 3 lots |
| Jun 15, 2026 (view filing)6:57 PM ET | Jun 11 | 4 days | RA Capital Healthcare Fund LP and 4 othersDirector, 10% Owner | PPurchaseVoting Common Stock | +21.2M | $20.00 | +$423.8M | New position2.65M after | 2 lots |
| Jun 15, 2026 (view filing) | Jun 11 | 4 days | Sebulsky AlanDirector | PPurchase | +12.5K | $20.00 | +$250.0K | New position12.5K after |
Top 10 13F holders, Q2 2026
See all 79 holdersThe largest institutional positions in Parabilis Medicines, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 28,933,371 | $791.9M | 6.88% | +28,933,371 | New |
| FMR LLC | 10,292,735 | $281.7M | 0.01% | +10,292,735 | New |
| ARCH Venture Management, LLC | 6,412,780 | $175.5M | 15.95% | +6,412,780 | New |
| venBio Partners LLC | 5,266,697 | $144.1M | 27.75% | +5,266,697 | New |
| Alphabet Inc. | 4,919,498 | $134.6M | 0.14% | +4,919,498 | New |
| Nextech Invest, Ltd. | 4,663,176 | $127.6M | 6.06% | +4,663,176 | New |
| Cormorant Asset Management, LP | 4,615,612 | $126.3M | 6.47% | +4,615,612 | New |
| Regeneron Pharmaceuticals, Inc. | 4,166,666 | $114.0M | 64.35% | +4,166,666 | New |
| Siren, L.L.C. | 2,992,259 | $81.9M | 1.66% | +2,992,259 | New |
| Farallon Capital Management, L.L.C. | 2,368,200 | $64.8M | 0.38% | +2,368,200 | New |
Holders of 5% or more of PBLS
See all 3 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Parabilis Medicines, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 13D | 23.80%28.9M shares | New | Jun 18, 20261 filing | Jun 18, 2026 | SEC |
| FMR LLC | 13G | 8.50%10.3M shares | New | Aug 6, 20261 filing | Aug 6, 2026 | SEC |
| ARCH Venture Fund XII, L.P. | 13G | 5.30%6.41M shares | New | Aug 14, 20261 filing | Aug 14, 2026 | SEC |